Interestingly, TET2 and CREBBP mutations are mutually exclusive in DLBCL (106), thus a combined mouse model could be engineered to find a potential therapeutic vulnerability in DLBCL. This evidence concerns the gene TET2 and diffuse large B-cell lymphoma.